Article
Combined Role of CYP3A4 and CYP3A5 genetic variants in tacrolimus dose-adjusted trough levels: a clinical retrospective study in kidney transplant patients.
The pharmacogenomics journal - 6 Jan 2026
Tsironi Anna, Mendrinou Effrosyni, Siamoglou Stavroula, Kydonopoulou Kyriaki, John Anne, Gerou Alexandra, Gerou Spyridon, Ali Bassam R, Papasotiriou Marios, Patrinos George P
Abstract excerpt
Tacrolimus, a calcineurin inhibitor with a narrow therapeutic index, requires precise dosing to optimize efficacy and minimize adverse effects in kidney transplant recipients. Although CYP3A5 genetic variants influence tacrolimus pharmacokinetics, they do not fully explain inter-individual differences. This retrospective study evaluated the combined impact of CYP3A4 [*1B (rs2740574), *1 G (rs2242480), *22...
Read the complete abstract on PubMed